
    
      The prognosis of patients with progressive and recurrent NK/T cell lymphoma is poor partially
      due to lack of effective treatment. L-asparaginase was reported to be effective in this
      setting by several case reports. The investigators aim to evaluate the efficacy and toxicity
      of L-asparaginase monotherapy in a prospective phase II study.
    
  